Arimidex in McCune Albright Syndrome
Study identifier:1033IL/0046
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in girls with McCune-Albright Syndrome
Medical condition
McCune-Albright Syndrome
Phase
Phase 2
Healthy volunteers
No
Study drug
Arimidex 1 mg
Sex
Female
Actual Enrollment
40
Study type
Interventional
Age
0 Years - 10 Years
Date
Study Start Date: 01 Aug 2002
Primary Completion Date: 01 Feb 2006
Study Completion Date: 01 Aug 2015
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2015 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Arimidex 1 mg Arimidex (anastrozole) 1mg once daily by mouth |
Contacts
Investigators
Principal Investigator
AstraZeneca Arimidex Medical Science Director
AstraZeneca
